KEYNOTE-671, KEYTRUDA, Merck, NSCLC, Pembrolizumab
Neoadjuvant/ adjuvant pembrolizumab is approved by the FDA for resectable non-small cell lung cancer
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
ARROW trial, Genentech, NSCLC, pralsetinib
Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions
August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), as determined by an FDA..
adagrasib, Krazati, Mirati Therapeutics, NSCLC, QIAGEN, RAS GTPase family inhibitor
Adagrasib gets accelerated approval for KRAS G12C-mutated NSCLC
Jan 2023: Adagrasib (Krazati, Mirati Therapeutics, Inc.), a RAS GTPase family inhibitor, was given accelerated approval by the Food and Drug Administration (FDA) for adult patients with KRAS G12C-mutated locally advanced or metast..
AstraZeneca Pharmaceuticals, durvalumab, Imjudo, NSCLC, POSEIDON, tremelimumab
Tremelimumab is approved by FDA in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer
November 2022: The combination of tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), and platinum-based chemotherapy was approved by the Food and Drug Administration for adult pa..
Libtayo, NCT03409614, NSCLC, platinum-based chemotherap, Regeneron Pharmaceuticals
Cemiplimab-rwlc is approved by FDA in combination with platinum-based chemotherapy for non-small cell lung cancer
November 2022: The combination of cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) and platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 abnormalit..
Capmatinib, NCT02414139, Novartis Pharmaceuticals Corp, NSCLC, Tabrecta
Capmatinib is approved for metastatic non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food..
BMS, CHECKMATE-816, nivolumab, NSCLC, Opdivo
Neoadjuvant nivolumab and platinum-doublet chemotherapy is approved for early-stage non-small cell lung cancer
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC).Thi..
Atezolizumab, Genentech, NSCLC, Tecentriq, Ventana Medical Systems, VENTANA PD-L1
Atezolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression o..
anaplastic lymphoma kinase, B7461006, CDx Assay, Food and Drug Administration, Lorbrena, lorlatinib, NCT03052608, NSCLC, Pfizer, Ventana ALK, Ventana Medical Systems
Lorlatinib has been approved by the FDA for the treatment of metastatic ALK-positive NSCLC
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..
cemiplimab-rwlc, EGFR, FDA, Food and Drug Administration, NCT03088540, NSCLC, PD-L1 expression
Cemiplimab-rwlc has been approved by the FDA for non-small cell lung cancer with high PD-L1 expression
August 2021: The FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgic..